11. Oktober 2022 Fighting Chronic Diseases and Cancer

As a result, it was not only possible to confirm the uptake of the enzyme by the cells. “We were also able to determine the spatial distribution of Q10 within the individual cells and to investigate how the uptake varied from one cell to the next. Interestingly enough, every single cell appeared to absorb Q10 whereby this depended on their respective sizes,” says the principal author and project leader Theresa Staufer, who is also co-leader of the group. For some time now, Grüner’s group has been focusing on refining X-ray fluorescence imaging so that it can be used even better as a tool for investigating the effect of molecular drug candidates in biological tissue samples.

Having performed validation measurements on an entire ball of cells at the P21.1 beamline, a tweaked method for individual cells was identified and implemented by a team led by DESY scientist Gerald Falkenberg on the beamline P06. “The high-resolution imaging we can achieve using the fine X-ray beam means that we can observe the labelled enzymes in the actual cell itself as if zooming in on it. So we are in fact measuring the markers, which are piggybacking on the enzymes actually under investigation,” Gerald Falkenberg explains the procedure.

The results of this refined method can be found in a number of publications, but also in patents. Next, the research is to be extended to the preclinical stage – i.e. developing new drugs. Together with other groups from the Department of Physics at the University of Hamburg, but also scientists from the University Medical Centre Hamburg-Eppendorf (UKE), Grüner’s group is planning to investigate labelled immune cells in chronic conditions such as Crohn's disease. Another project is focusing on anti-cancer agents, investigating whether these reach the tumour in large enough quantities and whether they also penetrate inside the tumour. The group recently received government funding for this research. There are also plans to apply the findings to studies on hepatitis and kidney diseases. Another project intends to track nanoparticles carrying mRNA, a topic that has been of considerable interest since the development of mRNA vaccines. All these projects rely on brilliant X-rays such as those generated at PETRA III.

“This research has enormous potential, which can be exploited above all through a close cooperation between the physics department of the University of Hamburg and the UKE. However, cooperation within Hamburg as a centre for science is just as important because we have a unique research infrastructure here, such as the facilities operated by DESY,” says Florian Grüner. For the current study alone, numerous partners played a crucial role: the Hamburg Fraunhofer Institute CAN labelled the Q10 molecules, and the X-ray fluorescence was measured in collaboration with a team from DESY’s PETRA III synchrotron, one of the most brilliant X-ray sources in the world. Beiersdorf AG, the company that commissioned the project, carried out the skin cell and biological tests on the labelled as compared with non-labelled Q10. “At such a unique research location, it will also be possible to translate promising findings from fundamental research into practical applications through technology transfer, in collaboration with industry,” says Grüner.